SAN DIEGO–(BUSINESS WIRE)—- $REVB #AKI–Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative therapies designed to rebalance the body’s inflammatory response, today announced a strategic shift designed to accelerate development of Gemini, its proprietary therapeutic candidate designed to restore the body’s natural inflammatory balance through multiple biological pathways. The strategy includes advancing a streamlined Phase

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.